Recombinant Anti-CD20 x Anti-CD22 Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-CD20 and anti-CD22 IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb is designed for the research of Lymphoma; Leukemia; Antoimmune disease; Immune dysfunction disease therapy.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRY